Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Natixis Advisors LLC

Natixis Advisors LLC cut its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 22.4% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 24,583 shares of the biopharmaceutical company’s stock after selling 7,077 shares during the quarter. Natixis Advisors LLC’s holdings in Intra-Cellular Therapies were worth $1,799,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of ITCI. Perceptive Advisors LLC boosted its position in shares of Intra-Cellular Therapies by 62.6% in the 2nd quarter. Perceptive Advisors LLC now owns 1,716,407 shares of the biopharmaceutical company’s stock worth $117,557,000 after buying an additional 661,052 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Intra-Cellular Therapies by 214.5% in the second quarter. Millennium Management LLC now owns 889,102 shares of the biopharmaceutical company’s stock valued at $60,895,000 after purchasing an additional 606,358 shares in the last quarter. Avoro Capital Advisors LLC lifted its holdings in shares of Intra-Cellular Therapies by 21.2% in the second quarter. Avoro Capital Advisors LLC now owns 3,000,000 shares of the biopharmaceutical company’s stock valued at $205,470,000 after purchasing an additional 525,000 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Intra-Cellular Therapies in the second quarter valued at approximately $34,178,000. Finally, Hood River Capital Management LLC purchased a new position in shares of Intra-Cellular Therapies during the 2nd quarter worth approximately $33,390,000. 92.33% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Intra-Cellular Therapies

In other news, CEO Sharon Mates sold 34,396 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $72.84, for a total transaction of $2,505,404.64. Following the completion of the transaction, the chief executive officer now directly owns 1,070,329 shares in the company, valued at approximately $77,962,764.36. This represents a 3.11 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, President Michael Halstead sold 22,869 shares of Intra-Cellular Therapies stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total transaction of $2,038,085.28. The disclosure for this sale can be found here. Company insiders own 2.60% of the company’s stock.

Intra-Cellular Therapies Price Performance

Shares of NASDAQ ITCI opened at $84.99 on Tuesday. Intra-Cellular Therapies, Inc. has a 1-year low of $58.14 and a 1-year high of $93.45. The company has a market capitalization of $9.01 billion, a price-to-earnings ratio of -98.49 and a beta of 0.97. The business has a 50-day moving average of $79.25 and a 200-day moving average of $74.84.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company had revenue of $175.40 million during the quarter, compared to analysts’ expectations of $172.30 million. During the same quarter in the prior year, the company earned ($0.25) EPS. The firm’s revenue was up 39.0% compared to the same quarter last year. Research analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ITCI has been the topic of several recent research reports. Royal Bank of Canada upped their price objective on Intra-Cellular Therapies from $106.00 to $108.00 and gave the company an “outperform” rating in a research report on Friday, October 4th. UBS Group decreased their price target on shares of Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Needham & Company LLC reiterated a “buy” rating and set a $100.00 price target on shares of Intra-Cellular Therapies in a report on Wednesday, October 30th. Cantor Fitzgerald reissued an “overweight” rating and set a $130.00 price objective on shares of Intra-Cellular Therapies in a research note on Monday, September 16th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an “overweight” rating in a research note on Monday, November 4th. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $97.23.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.